Page last updated: 2024-08-16

(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and Body Weight

(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with Body Weight in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andrzejak, V; Barczyk, A; Body-Malapel, M; Chavatte, P; Desreumaux, P; Djouina, M; Leleu-Chavain, N; Millet, R; Rigo, B; Tourteau, A1

Other Studies

1 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and Body Weight

ArticleYear
Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
    Bioorganic & medicinal chemistry letters, 2014, Mar-01, Volume: 24, Issue:5

    Topics: Adamantane; Amidohydrolases; Animals; Anti-Inflammatory Agents; Body Weight; Cannabinoids; Colitis; Disease Models, Animal; Enzyme Inhibitors; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Protein Binding; Receptor, Cannabinoid, CB2; Structure-Activity Relationship

2014